Griffith-led team analyzing 116 cohorts proposes barrier-cell energy failure may underlie some allergies
A new hypothesis paper in Allergy reinterprets allergy as possibly starting with energy failure in barrier cells, not immune misfires. Its strongest data come from eosinophilic esophagitis, with weaker or absent signals in other allergic conditions, so it is important but not settled.
Peter Smith, a clinical immunologist at Griffith University, and colleagues published a hypothesis paper in Allergy arguing that some allergic diseases may begin inside epithelial cells that line the skin, gut, nose, lungs and esophagus. The team reviewed a multi-omic collection it described as the largest allergy data set it knew of, covering 116 case-control cohorts, 3,776 patients and 2,164 controls, with co-authors from Mount Sinai, Leuven, Cork, Southampton, Zurich, Miami, Singapore and Aberdeen.
The strongest signal appeared in eosinophilic esophagitis, an allergic inflammation of the esophagus, where the pathway cells use to clear damaged mitochondria was reduced in all 13 independent patient cohorts. In eczema, changes in skin barrier and antioxidant defenses were reported even in skin that was not inflamed. The pattern was not universal: it was absent in established asthma and nasal polyps and only partly present in hay fever, limiting how broadly the idea applies.
The paper proposes that many environmental and lifestyle factors, including processed diets, pollution, microplastics, detergents, loss of dietary fiber and early antibiotic exposure, may converge on one shared target: the energy capacity of barrier cells. If those cells cannot meet stress demands, they may raise alarm signals before immune events recognized as allergy follow. The authors also suggest established inflammation can further damage the barrier, helping explain relapse after treatment stops when drugs act downstream.
For families, the hypothesis matters because allergic diseases already affect up to one in three children, according to the study's framing, and current therapies often manage symptoms rather than repair the barrier. But the evidence is observational and hypothesis-generating: case-control omic associations cannot show that mitochondrial energy failure causes allergy. The authors state the next step is to measure these cells directly in infants before allergy develops, a prospective design needed to test timing and causation.
It could reshape how researchers study and treat allergies that affect many children, by pointing to barrier-cell energy as an upstream target, but the evidence is still observational and needs direct testing before conclusions.
Sources (1)
- [1]Some allergies may start with cells running short of energy, not immune system misfires(https://medicalxpress.com/news/2026-11-allergies-cells-short-energy-immune.html)